



**Date: September 30, 2024**

**BSE Limited**  
P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Script Code: 543904**

**Symbol: MANKIND**

Dear Sir/ Madam,

**Subject: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Intimation of Credit Rating**

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that ICRA Limited vide their letter dated September 30, 2024 has assigned/reaffirmed the credit ratings for the following instruments:

<b>Credit Rating Company</b>	<b>Instrument</b>	<b>Amount (₹ crore)</b>	<b>Rating</b>	<b>Rating Action</b>
ICRA Limited	Commercial Paper	5,000.00	[ICRA]A1+	Assigned
	Non-Convertible Debentures	4,600.00	[ICRA]AA+(Stable)	Reaffirmed
	Non-Convertible Debentures	400.00	[ICRA]AA+(Stable)	Assigned
	Long Term-Fund Based-Working Capital Limits	750.00	[ICRA]AA+(Stable)	Assigned
	Long Term-Fund Based-Term Loans	500.00	[ICRA]AA+(Stable)	Assigned

The above information is also available on the website of the Company at [www.mankindpharma.com](http://www.mankindpharma.com).

This is for your information and records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Pradeep Chugh**  
Company Secretary and Compliance Officer

**MANKIND PHARMA LIMITED**